Allergy

Global Meal Kit Markets Report 2023-2024 & 2029 Featuring HelloFresh, Marley Spoon, Blue Apron, Home Chef, FreshDirect, Fresh N Lean, Green Chef, The Purple Carrot, Gousto, Sunbasket, Gobble, Dinnerly - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Food, Beverage, Retail, Online, Cooking, Eating, Meat, Vitamin, Urbanization, Growth, COVID-19, Social media, Female, Mineral, Niacin, Thiamine, HelloFresh, Restaurant, Allergy, Market, Food delivery

In 2023, the global meal kit market was valued at US$17.44 billion, and is probable to reach US$38.81 billion by 2029.

Key Points: 
  • In 2023, the global meal kit market was valued at US$17.44 billion, and is probable to reach US$38.81 billion by 2029.
  • The global meal kit market value is projected to grow at a CAGR of 14.26%, during the forecast period of 2024-2029.
  • Hellofresh is the largest and most relevant player with ~50% of the global market share.
  • Moreover, online distribution channels allow meal kit companies to reach a broader audience, not limited by geographical boundaries, which aids in widening the potential customer base.

AllerVie Health Strengthens Leadership Team with VP Promotions and New Hire

Retrieved on: 
Thursday, March 28, 2024
Hospitals, Health Technology, Health, Practice Management, MD, Minyard, Patient, Multimedia, P&L, Allergy, Growth, Human resources, Acquisition, Management

Today, AllerVie Health , a national network of allergy clinics, announces several key vice president promotions and a new hire to its executive team.

Key Points: 
  • Today, AllerVie Health , a national network of allergy clinics, announces several key vice president promotions and a new hire to its executive team.
  • These strategic leadership moves solidify AllerVie Health's position as a frontrunner in allergy and immunology, with a continued focus on delivering exceptional care.
  • View the full release here: https://www.businesswire.com/news/home/20240327321188/en/
    "Our recent executive promotions and addition of a new VP represent our commitment to building a strong leadership team capable of driving innovation and delivering exceptional care to our patients," said Tae Kim, AllerVie Health CEO.
  • With a focus on collaboration, innovation, and continuous improvement, AllerVie Health is poised for continued growth and success in the healthcare landscape.

Clinique Launches in the U.S. Amazon Premium Beauty Store

Retrieved on: 
Wednesday, March 27, 2024
Women, Men, Technology, Electronic Commerce, Online Retail, Consumer, Cosmetics, Retail, Honey, Education, Hyperpigmentation, State, Allergy, Red, Dermatology, Acne, Dehydration, Skin, Safety, Clinique, Consultant

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.

Key Points: 
  • Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.
  • Developed with Clinique’s Guiding Dermatologists, this interactive questionnaire in Amazon Premium Beauty will custom-fit a skincare regimen for Clinique’s consumers, ensuring a simplified and personalized skincare journey, with recommended products available for purchase from Amazon’s Premium Beauty store.
  • “We are delighted to introduce Clinique to new consumers in the U.S and make it accessible for the beauty-savvy community in the Amazon Premium Beauty store,” said Michelle Freyre, Global Brand President, Clinique.
  • “Clinique is a beauty brand revered around the world, drawing on a rich heritage of dermatological expertise, and beloved across generations of customers,” said Melis del Rey, G.M., Amazon U.S. Stores Beauty, Baby, and Beauty Technology.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Interest, Dizziness, Attack, Disease, PD, Webcast, Patient, HAE, Allergy, Quality of life, IND, Injection site reaction, Rash, Plasma kallikrein, Investment, Therapy, Hereditary angioedema, Safety, Charité, Pharmacokinetics, Pain, Multimedia, Pharmaceutical industry

Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.

Key Points: 
  • Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.
  • Initial safety and efficacy data from Q3M and Q6M dosing in the ALPHA-SOLAR trial are expected mid-2025.
  • Pending regulatory feedback, the Company expects to start a pivotal Q3M Phase 3 trial in Q1 2025, with top-line results expected by year-end 2026.
  • Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com or with following the link https://lifescievents.com/event/astriatx/ .

Deepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform Launch

Retrieved on: 
Wednesday, March 13, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Artificial Intelligence, Science, Biotechnology, Stem Cells, Health, Gene, Flow cytometry, Gene expression, Intelligence, Cell biology, Allergy, Newcastle University, Developmental biology, Doctor of Philosophy, Genotype, EMBL, Axon, Eosinophil, Cognition, Neutrophil, Liver cancer, Machine learning, European, Bone marrow, Microscope

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .

Key Points: 
  • Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .
  • The participants will use the technology to study plasma disorders, blood cancers, immunological functions, genetic perturbations, and other cellular processes.
  • The REM-I platform is a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, an AI Foundation Model, and Axon data suite.
  • “Deepcell's method of integrating artificial intelligence and single cell analysis remains unique in the industry,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

John B. Sanfilippo & Son, Inc Issues Allergy Alert on Undeclared Coconut and Milk in Great Value Honey Roasted Cashews 8.25 Oz

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Men, General Health, Family, Supermarket, Consumer, Food, Beverage, Fitness & Nutrition, Retail, Other Consumer, Women, Health, Honey, Risk, CDT, Walmart, Allergy, Milk

John B. Sanfilippo & Son, Inc (JBSS) announced today it is voluntarily recalling a limited amount of 8.25 oz Great Value Honey Roasted Cashews, because it may contain undeclared coconut and milk.

Key Points: 
  • John B. Sanfilippo & Son, Inc (JBSS) announced today it is voluntarily recalling a limited amount of 8.25 oz Great Value Honey Roasted Cashews, because it may contain undeclared coconut and milk.
  • Product was distributed in select Walmart stores within the following states:
    The recall was initiated after a consumer report of finding coconut cashews within a container labeled as honey roasted cashews.
  • An investigation identified that a limited number of incorrect honey roasted cashew labels were applied to the plastic cans of coconut cashews during the manufacturing process.
  • Consumers with questions may contact John B. Sanfilippo & Son, Inc. at 1-800-874-8734 Monday – Friday, 8:00am – 5:00pm CDT, or via email at [email protected] .

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

Ready. Set. Food! and ObvioHealth Launch Innovative Trial to Correlate Infant Food Allergy Prevention with Reduced Healthcare Costs

Retrieved on: 
Thursday, March 28, 2024
Food, Pediatrics, Parent, Risk, Allergy, Infant, Insurance, Trial of the century, Health, Food allergy, Caregiver, Multimedia, Allergen

NEW YORK, March 28, 2024 /PRNewswire/ -- Ready. Set. Food! announces the launch of a pioneering clinical study (EASE trial) with ObvioHealth, which will use real-world infant healthcare data to assess how the convenient and early introduction of common food allergens impacts infant allergies and associated healthcare costs.     

Key Points: 
  • Food!
  • Food!
  • announces the launch of a pioneering clinical study (EASE trial) with ObvioHealth , which will use real-world infant healthcare data to assess how the convenient and early introduction of common food allergens impacts infant allergies and associated healthcare costs.
  • Food!